Literature DB >> 18802802

Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals.

David J Alexander1, Christopher J Collins, Derek W Coombs, Ian S Gilkison, Colin J Hardy, Graham Healey, George Karantabias, Neil Johnson, Anna Karlsson, Joanne D Kilgour, Paddy McDonald.   

Abstract

There are many ways in which the dose can be expressed in inhalation toxicology studies. This can lead to confusion when comparing results from studies performed in different laboratories. A working party of the Association of Inhalation Toxicologists has reviewed this subject in detail and has collected data from 10 inhalation laboratories and used these data to determine a new algorithm for the calculation of Respiratory Minute Volume (RMV), one of the most important factors in the calculation of delivered dose. The recommendations of the working party for regulatory inhalation toxicology studies with pharmaceuticals are as follows: 1. The dose should be reported as the delivered dose calculated according to the formula: DD = C x RMV x D(xIF)/BW, where DD = delivered dose (mg/Kg); C = concentration of substance in air (mg/L); RMV =respiratory minute volume or the volume of air inhaled in one minute (L/min); D = duration of exposure (min); IF = proportion by weight of particles that are inhalable by the test species, the inhalable fraction (inclusion of this parameter is not essential provided that the aerosol has reasonable respirability for the intended species. If it is included, the way in which it is determined should be clearly stated); BW = bodyweight (Kg). 2. The RMV for mice, rats, dogs and cynomolgus monkeys should be calculated according to the formula:RMV(L/min) = 0.608 x BW(Kg)(0.852). 3. If deposited dose or the amount of material actually retained inthe respiratory tract is presented as supplementary information,the way in which it is calculated should be clearly stated.4. Dose should always be presented in mg/Kg but may also bepresented in other ways, such as mg/unit body surface area, as supplementary information.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802802     DOI: 10.1080/08958370802207318

Source DB:  PubMed          Journal:  Inhal Toxicol        ISSN: 0895-8378            Impact factor:   2.724


  40 in total

1.  Distribution of aerosols in mouse lobes by fluorescent imaging.

Authors:  Dandan Yi; Amir Naqwi; Angela Panoskaltsis-Mortari; Timothy Scott Wiedmann
Journal:  Int J Pharm       Date:  2012-01-25       Impact factor: 5.875

2.  NOS-2 Inhibition in Phosgene-Induced Acute Lung Injury.

Authors:  Piotr T Filipczak; Albert P Senft; JeanClare Seagrave; Waylon Weber; Philip J Kuehl; Laura E Fredenburgh; Jacob D McDonald; Rebecca M Baron
Journal:  Toxicol Sci       Date:  2015-04-13       Impact factor: 4.849

Review 3.  Comprehensive review of epidemiological and animal studies on the potential carcinogenic effects of nicotine per se.

Authors:  Hans-Juergen Haussmann; Marc W Fariss
Journal:  Crit Rev Toxicol       Date:  2016-06-09       Impact factor: 5.635

4.  In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.

Authors:  Yi-Bo Wang; Alan B Watts; Jay I Peters; Sha Liu; Ayesha Batra; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2014-05-14       Impact factor: 3.246

5.  Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.

Authors:  Paul M Beringer; Timothy J Bensman; Henry Ho; Melissa Agnello; Nicole Denovel; Albert Nguyen; Annie Wong-Beringer; Rosemary She; Dat Q Tran; Samuel M Moskowitz; Michael E Selsted
Journal:  J Antimicrob Chemother       Date:  2015-10-03       Impact factor: 5.790

6.  Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.

Authors:  Timothy J Bensman; Jordanna G Jayne; Meiling Sun; Elza Kimura; Joshua Meinert; Joshua C Wang; Justin B Schaal; Dat Tran; Adupa P Rao; Omid Akbari; Michael E Selsted; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Development, Characterization, and Standardization of a Nose-Only Inhalation Exposure System for Exposure of Rabbits to Small-Particle Aerosols Containing Francisella tularensis.

Authors:  Katherine J O'Malley; Jennifer D Bowling; Eileen M Barry; Karsten R O Hazlett; Douglas S Reed
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

8.  Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model.

Authors:  James Verco; William Johnston; Michael Baltezor; Philip J Kuehl; Andrew Gigliotti; Steven A Belinsky; Anita Lopez; Ronald Wolff; Lauren Hylle; Gere diZerega
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-25       Impact factor: 2.849

9.  Breath-by-breath measurement of particle deposition in the lung of spontaneously breathing rats.

Authors:  S Karrasch; G Eder; I Bolle; A Tsuda; H Schulz
Journal:  J Appl Physiol (1985)       Date:  2009-07-30

10.  Development of a rhesus monkey lung geometry model and application to particle deposition in comparison to humans.

Authors:  Bahman Asgharian; Owen Price; Gene McClellan; Rick Corley; Daniel R Einstein; Richard E Jacob; Jack Harkema; Stephan A Carey; Edward Schelegle; Dallas Hyde; Julia S Kimbell; Frederick J Miller
Journal:  Inhal Toxicol       Date:  2012-11       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.